SNCA genetic lowering reveals differential cognitive function of alpha-synuclein dependent on sex

Antisense oligonucleotide (ASO) therapy for neurological disease has been successful in clinical settings and its potential has generated hope for Alzheimer’s disease (AD). We previously described that ablating SNCA encoding for α-synuclein (αSyn) in a mouse model of AD was beneficial. Here, we soug...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Jennifer L., Hart, Damyan W., Boyle, Gabriel E., Brown, Taylor G., LaCroix, Michael, Baraibar, Andrés M., Pelzel, Ross, Kim, Minwoo, Sherman, Mathew A., Boes, Samuel, Sung, Michelle, Cole, Tracy, Lee, Michael K., Araque, Alfonso, Lesné, Sylvain E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749314/
https://www.ncbi.nlm.nih.gov/pubmed/36517890
http://dx.doi.org/10.1186/s40478-022-01480-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749314/
https://www.ncbi.nlm.nih.gov/pubmed/36517890
http://dx.doi.org/10.1186/s40478-022-01480-y

Ejemplares similares